Peptides for muscle growth: what’s legal and what isn’t

No peptide is FDA-approved to build muscle, and as of Oct 27, 2026 a licensed pharmacy may not compound the peptides and related compounds sold for muscle growth, including BPC-157, TB-500, CJC-1295, ipamorelin, GHRP-6, MK-677 and AOD-9604. All of them are banned in tested sport, and testosterone, an FDA-approved hormone, is a controlled substance whose injection is approved to replace testosterone in men with diagnosed hypogonadism, not to build muscle. This guide lists what is sold, where each stands with the FDA and WADA, and how peptides compare with steroids. It covers legal status only, not dosing or results.

Muscle peptides and where each one stands

A peptide can reach you lawfully in only two ways: as an FDA-approved drug, or compounded by a licensed pharmacy from an ingredient that has a USP monograph, is part of an approved drug, is on the FDA’s 503A bulks list, or sits in its Category 1 under the FDA’s interim policy (FDA). Category 2 holds substances that may present significant safety risks, and Category 3 holds substances nominated without enough support. Neither can be compounded.

Scroll sideways to see the full table

Sources: FDA categories list updated May 14, 2026 (FDA), FDA safety-risks page (FDA), advisory committee minutes for Oct 29, 2024 and Dec 4, 2024, and WADA’s 2026 list (WADA).

What the FDA has decided, peptide by peptide

Growth hormone releasers: CJC-1295, ipamorelin, GHRPs and MK-677

Most “muscle peptides” are sold to make the pituitary release more growth hormone. The FDA has reviewed several of them for medical uses, and it has proposed keeping each one off the compounding list.

• CJC-1295. Reviewed for growth hormone deficiency. On Dec 4, 2024, the committee voted 13 to 0 against the free base and 12 to 1 against the acetate salt (FDA minutes).
• Ipamorelin. Reviewed for growth hormone deficiency and slow gut recovery after surgery. On Oct 29, 2024, the committee voted 12 to 0, with 1 abstention, against both forms (FDA minutes).
• Ibutamoren (MK-677). Reviewed for growth hormone deficiency, osteoporosis, hip fracture, sarcopenia (age-related muscle loss), obesity and Alzheimer’s disease. The committee voted 13 to 1 against it, and several members raised concerns about reported fluid retention, congestive heart failure and high blood sugar. It has been in Category 2 for 503A pharmacies since Sep 29, 2023; the FDA notes a placebo-controlled trial in people recovering from hip fracture that “was terminated early due to a potential safety signal of congestive heart failure.”
• GHRP-2 and GHRP-6. Both are in 503A Category 3, nominated without adequate support, and in Category 2 for outsourcing facilities since Sep 29, 2023 (GHRP-2 for injected and nasal forms).

Of these reviews, sarcopenia is the use closest to muscle growth, and the advisers voted against ibutamoren for it.

Repair peptides: BPC-157 and TB-500

BPC-157 and TB-500 are sold for recovery and injuries. The FDA’s safety page, last updated Apr 22, 2026, lists both as “nominated but withdrawn”, which leaves them in no category. On July 23, 2026, an FDA advisory committee voted 8 to 6, with 1 abstention, to recommend adding each of them to the bulks list, BPC-157 for ulcerative colitis and TB-500 for wound healing, according to law-firm reports of the meeting (McDermott). The FDA has not posted minutes for that meeting or published a proposed rule, so neither can be compounded yet. For TB-500, the FDA says it “has not identified any human exposure data”. Our guide to BPC-157 vs TB-500 covers both.

Fat and growth factor peptides: AOD-9604 and MGF

AOD-9604 is a fragment of human growth hormone that failed as an obesity drug, and FDA advisers voted 12 to 0 against it in December 2024. Mechano growth factor is in 503A Category 3, and for the pegylated form, PEG-MGF, the FDA says it “has not identified any human exposure data”. Neither has an approved use.

Peptides vs steroids

People often weigh peptides against anabolic steroids. The comparison that matters is legal status, because neither group is approved for building muscle in healthy people.

The DEA lists “anabolic steroids” and testosterone in Schedule III; none of the peptides above appears on its list, dated Oct 21, 2026 (DEA). That doesn’t make the peptides legal to sell. In a June 2023 warning letter, the FDA told a seller that its BPC-157, TB-500 and MK-677 products were unapproved new drugs, despite labels saying “research purpose only” (FDA).

Growth hormone itself sits under a separate law. Federal law makes it a crime to knowingly distribute human growth hormone “for any use in humans other than the treatment of a disease or other recognized medical condition” authorized by HHS and ordered by a physician, punishable by up to 5 years in prison (21 U.S.C. 333(e)).

The approved option: testosterone, and who it is for

Testosterone gel carries a boxed warning: virilization (male physical changes) has been reported in children secondarily exposed to the gel, so children should avoid contact with unwashed or unclothed application sites (AndroGel label). The testosterone cypionate injection label (Depo-Testosterone) has no boxed warning.

Testosterone injection is FDA-approved as “replacement therapy” in men with primary hypogonadism or hypogonadotropic hypogonadism, conditions where the body makes too little testosterone. Its label says safety and efficacy in men with “age-related hypogonadism” have not been established, and it warns that testosterone “has been subject to abuse, typically at doses higher than recommended”, which “can lead to serious cardiovascular and psychiatric adverse reactions” (Depo-Testosterone label). Prescribing it to build muscle in a man with normal levels is not an approved use.

Testosterone is a Schedule III controlled substance. Prescribing it by telemedicine without an in-person visit relies on a DEA and HHS extension that runs through Dec 31, 2026 (Federal Register). If you think your testosterone is low, a clinician can test your level and decide whether treatment fits. See the testosterone injection page, our signs of low testosterone guide and how to get TRT online.

The two peptides a clinician can prescribe

Sermorelin was approved as Geref in 1990 and 1997 and discontinued in 2008; in 2013 the FDA found it was not withdrawn for safety or effectiveness (Federal Register). That lets a 503A pharmacy compound it. Compounded sermorelin is not FDA-approved, and using it for muscle or body composition is off-label.

Tesamorelin (Egrifta SV) is approved only to reduce excess abdominal fat in adults with HIV who have lipodystrophy. Its label says it is not indicated for weight loss management (DailyMed). It can’t be compounded. Our tesamorelin vs sermorelin guide compares them.

What about peptides labeled for research?

Many muscle peptides are sold online in vials labeled for laboratory research. Buying these to inject is unsafe and unregulated. No prescriber checks whether it suits you, no licensed pharmacy answers for what is in the vial, and no one has verified its identity, strength or sterility. A website that offers a “prescription” for compounded CJC-1295, ipamorelin, BPC-157 or MK-677 today is offering something a licensed pharmacy may not lawfully make. Our guide on whether peptides are safe covers how to check a provider.

The bottom line

No peptide is approved to build muscle, and the ones most sold for it have no lawful prescription source as of Oct 27, 2026. FDA advisers rejected CJC-1295, ipamorelin, MK-677 and AOD-9604 in 2024, BPC-157 and TB-500 await an FDA decision after July’s votes, and WADA bans all of them. The approved options are narrower than the marketing: testosterone for diagnosed hypogonadism, compounded sermorelin off-label and tesamorelin for one HIV-related use. For every peptide’s status, see are peptides legal in 2026 or the peptides hub.